Company intelligence / Profile preview

Fertiga

Ownership: Private
Development stage: Commercial

Overview

The Aurora Test by Fertiga uses cumulus cell analysis as a non-invasive method to select the most competent oocytes and embryos during IVF. Clinical results presented at ESHRE show that using the test can reduce embryo culture workload and increase pregnancy rates in fresh transfer cycles. Retrospective studies indicate improved outcomes when selecting top-ranking oocytes with this approach.

Therapeutic areas: Women's Health
Modalities: Diagnostic test (specifically, cumulus cell analysis)Non-pharmacological therapy (as it relates to IVF support)
Industry: Molecular Diagnostics

Partnerships

Not explicitly listed; close academic ties with UZ Brussels and VUB Center of Reproductive Medicine.

Beyond the preview

Go deeper on Fertiga.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fertiga.

Explore the full profile